Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R; Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH). Martínez C, et al. Among authors: vallansot r. Ann Hematol. 2023 Feb;102(2):429-437. doi: 10.1007/s00277-022-05011-6. Epub 2022 Nov 12. Ann Hematol. 2023. PMID: 36370191 Free article.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). García-Gutiérrez V, et al. Among authors: vallansot ro. Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Ann Hematol. 2019. PMID: 30446802 Clinical Trial.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Hernández-Boluda JC, et al. Among authors: vallansot r. Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0. Blood Cancer J. 2018. PMID: 30504932 Free PMC article.
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.
Estrada N, Xicoy B, Beier F, Garcia O, Morales C, Boqué C, Sagüés M, Ventura Ferreira MS, Vallansot R, Marcé S, Cabezón M, Brümmendorf TH, Zamora L. Estrada N, et al. Among authors: vallansot r. Hemasphere. 2021 Nov 30;5(12):e657. doi: 10.1097/HS9.0000000000000657. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34853825 Free PMC article.
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.
Estrada N, Zamora L, Ferrer-Marín F, Palomo L, García O, Vélez P, De la Fuente I, Sagüés M, Cabezón M, Cortés M, Vallansot RO, Senín-Magán MA, Boqué C, Xicoy B. Estrada N, et al. Among authors: vallansot ro. J Clin Med. 2022 Oct 21;11(20):6217. doi: 10.3390/jcm11206217. J Clin Med. 2022. PMID: 36294538 Free PMC article.
Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia.
Ortí G, García-Gutiérrez V, Bautista G, Ferrer-Marín F, Vallansot R, Xicoy B, Sánchez À, Simon I, Triguero A, Sierra M, Casado LF; Grupo Español de Leucemia Mieloide Crónica (GELMC). Ortí G, et al. Among authors: vallansot r. Leuk Res. 2022 Oct;121:106923. doi: 10.1016/j.leukres.2022.106923. Epub 2022 Aug 4. Leuk Res. 2022. PMID: 35933910 No abstract available.
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Steegmann JL, et al. Among authors: vallansot r. J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. J Cancer Res Clin Oncol. 2017. PMID: 28551768 Free PMC article.
Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
Maffioli M, Camós M, Gaya A, Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, Granell M, Guillem V, Vallansot R, Costa D, Bellosillo B, Colomer D, Cervantes F. Maffioli M, et al. Among authors: vallansot r. Leuk Res. 2011 Aug;35(8):1014-9. doi: 10.1016/j.leukres.2010.12.004. Epub 2010 Dec 24. Leuk Res. 2011. PMID: 21185600
Giant-cell anaplastic lymphoma in an open thoracostomy cavity.
Ramos R, Ureña A, Martinez S, Spuch JA, Vallansot R. Ramos R, et al. Among authors: vallansot r. Cir Esp. 2015 Dec;93(10):670-2. doi: 10.1016/j.ciresp.2014.07.005. Epub 2014 Nov 20. Cir Esp. 2015. PMID: 25438775 English, Spanish. No abstract available.
17 results